RA
FENC icon

Rosalind Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Rosalind Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.9M Buy
2,908,201
+294,693
+11% +$2.28M 7.19% 3
2025
Q4 		$20.1M Buy
2,613,508
+536,668
+26% +$4.41M 7.07% 3
2025
Q3 		$19.4M Buy
2,076,840
+31,196
+2% +$270K 6.64% 3
2025
Q2 		$17M Buy
2,045,644
+262,800
+15% +$1.8M 8.05% 2
2025
Q1 		$10.9M Buy
1,782,844
+522,968
+42% +$3.36M 5.28% 6
2024
Q4 		$7.96M Buy
+1,259,876
New +$6.45M 4.07% 10

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rosalind Advisors's FENC Position: Q1 2026 in Review

Rosalind Advisors increased its Fennec Pharmaceuticals (FENC) stake by 11% in Q1 2026, buying an estimated $2.28M and bringing the position to 2,908,201 shares worth $17.9M. The position accounts for 7.19% of the portfolio, ranked #3.

Rosalind Advisors first reported a position in FENC in Q4 2024 and has held it in 6 quarters since. The position peaked at $20.1M in Q4 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Rosalind Advisors held 2,908,201 shares of Fennec Pharmaceuticals worth $17.9M as of Q1 2026.
  • Rosalind Advisors bought 294,693 Fennec Pharmaceuticals shares in Q1 2026, an estimated $2.28M.
  • Fennec Pharmaceuticals made up 7.19% of Rosalind Advisors's portfolio in Q1 2026, its #3 holding.
  • Rosalind Advisors first reported a position in Fennec Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Rosalind Advisors's Fennec Pharmaceuticals position peaked at $20.1M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.